DATES: Because scheduled vacancies occur on various dates throughout each year, no cutoff date is established for the receipt of nominations. However, when possible, nominations should be received at least 6 months before the date of scheduled vacancies for each year, as indicated in this notice.

ADDRESSES: All nominations and curricula vitae should be sent to the appropriate contact person in the **FOR FURTHER INFORMATION CONTACT** section of this document.

FOR FURTHER INFORMATION CONTACT:

Regarding nominations except for consumer representatives: Jane Brown, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–0314.

Regarding nominations for consumer representatives: Linda Sherman, Advisory Committee Oversight and Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations of voting members with appropriate expertise for vacancies listed as follows:

1. Allergenic Products Advisory Committee: Three vacancies occurring August 31, 2003; immunology, pediatrics, internal medicine, biochemistry, statistics, consumer interest, and related scientific fields.

2. Blood Products Advisory Committee: One vacancy occurring in September 30, 2002, and six vacancies occurring on September 30, 2003; clinical and administrative medicine, hematology, immunology, blood banking, surgery, internal medicine, biochemistry, engineering, statistics, biological and physical sciences, and other related scientific fields.

3. Transmissible Spongiform Encephalopathies Advisory Committee: Five vacancies occurring January 31, 2003; clinical administrative medicine, hematology, virology, neurology, infectious diseases, immunology, blood banking, surgery, internal medicine, biochemistry, biostatistics, epidemiology, biological and physical sciences, sociology/ethics, and other related professions.

4. Vaccines and Related Biological Products Advisory Committee: Five vacancies occurring in January 31, 2003; immunology, molecular biology, recombinant deoxyribonucleic acid (rDNA), virology, bacteriology, epidemiology, biostatistics, allergy, preventive medicine, infectious diseases, pediatrics, microbiology, biochemistry, and consumer interest.

Functions

1. *Allergenic Products Advisory Committee*

Reviews and evaluates available data concerning the safety, effectiveness, and adequacy of labeling of marketed and investigational allergenic biological products or materials that are administered to humans for the diagnosis, prevention, or treatment of allergies and allergic diseases.

2. *Blood Products Advisory Committee*

Reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood and products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases.

3. *Transmissible Spongiform Encephalopathies Advisory Committee*

Reviews and evaluates available scientific data concerning the safety of products which may be at risk for transmission of spongiform encephalopathies having an impact on the public health.

4. *Vaccines and Related Biological Products Advisory Committee*

Reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases.

Qualifications

Persons nominated for membership on the committees shall have adequately diversified experience appropriate to the work of the committee in such fields as clinical and administrative medicine, engineering, biological and physical sciences, statistics, and other related professions. The nature of specialized training and experience necessary to qualify the nominee as an expert suitable for appointment may include experience in medical practice, teaching, and/or research relevant to the field of activity of the committee. The particular needs at this time for each committee are shown in section I of this document. The term of office is up to 4 years, depending on the appointment date.

Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on one or more of the advisory committees. Self-nominations are also accepted. Nominations shall include the name of the committee, a complete curriculum vitae of each nominee, current business address and telephone number, and shall state that the nominee is aware of the nomination, is willing to serve as a member (name of committee(s) must be specified), and appears to have no conflict of interest that would preclude membership. FDA will ask the potential candidates to provide detailed information concerning such matters as financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflict of interest.

Consumer Representatives

Any interested person may nominate one or more qualified persons for membership on one or more of the advisory committees to represent consumer interests. Self-nominations are also accepted. To be eligible for selection, the applicant's experience and/or education will be evaluated against Federal civil service criteria for the position to which the person will be appointed.

Selection of members representing consumer interests is conducted through consumer organizations that have the responsibility for recommending candidates for the agency's selection. Candidates should possess appropriate qualifications to understand and contribute to the committee's work.

Nominations shall include a complete curriculum vita of each nominee, current address and telephone numbers, and shall state that the nominee is aware of the nomination, is willing to serve as a member, and appears to have no conflict of interest that would preclude membership. FDA will ask the potential candidates to provide detailed information concerning such matters as financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflict of interest. The nomination should state whether the nominee is interested only in a particular advisory committee or in any advisory committee. The term of office is up to 4 years, depending on the appointment date.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

Dated: July 5, 2002.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 02–17514 Filed 7–11–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Evidence Based Assisted Reproductive Technologies; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

The Food and Drug Administration (FDA) in cosponsorship with the National Institutes of Health (NIH), and Department of Health and Human Services (DHHS), Office of Women's Health is announcing the following public workshop entitled: ''Evidence Based Assisted Reproductive Technologies (ART).'' The topics to be discussed include: (1) The FDA regulatory framework; (2) methods of supporting research in this area by NIH; and (3) scientific, social, ethical and policy issues concerning ART.

Date and Time: The public workshop will be held on September 18, 2002, from 8:30 a.m. to 4:30 p.m., and September 19, 2002, from 8 a.m. to 12 a.m.

Location: The public workshop will be held at Lister Hill Center, Bldg. 38A, NIH, 8600 Rockville Pike, Bethesda, MD.

Contact Person: *For information about this notice*: Michael D. Anderson, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–6210, FAX 301–594–1944.

For information about the public workshop: Melanie Whelan, Center for Biologics Evaluation and Research (HFM–40), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3079, FAX 301–827–3843, or e-mail: whelan@cber.fda.gov.

Registration: Send registration information (including name, title, firm name, address, telephone, and fax number) to Melanie Whelan (see *Contact Person*) by Friday, September 6, 2002. The registration form is available at http://www.fda.gov/cber/meetings.htm. There is no registration fee for the public workshop. Space is limited, therefore interested parties are encouraged to register early. There will be no onsite registration.

If you need special accommodations due to a disability, please contact Melanie Whelan at least 7 days in advance.

SUPPLEMENTARY INFORMATION: This public workshop will provide a forum for discussion of scientific, social, ethical, and policy issues related to ART. The public workshop will be of primary interest to consumers, researchers, academia, ART practitioners, and sponsors of clinical trials evaluating novel ART. The goals of the public workshop are to: (1) Assess the usefulness of animal models in evaluating the safety and efficacy of human ART, and (2) identify social and ethical issues specific to ART. These issues are of interest to FDA, NIH, and DHHS to guide development of scientific initiatives, policy, and regulations in this area and to identify areas where research funding may be needed.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The transcript of the workshop will also be available on the Internet at http://www.fda.gov/cber/minutes/workshop-min.htm.

Dated: July 8, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 02–17584 Filed 7–11–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Pediatric Oncology Drug Development; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

The Food and Drug Administration (FDA) is announcing a public workshop, cosponsored with the American Academy of Pediatrics (AAP), regarding pediatric oncology drug development. The public workshop is intended to provide information for and perspective from advocacy groups, interested health care providers, academia, and industry organizations on various aspects of drug development in pediatric oncology, including prioritization of new and emerging therapeutic alternatives, clinical trial design, and access to new therapeutic agents. The input from this public workshop will be used in developing topics for discussion at future meetings of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (the subcommittee).

Date and Time: The public workshop will be held on Thursday, July 18, 2002, from 8 a.m. to 4 p.m.

Location: The public workshop will be held in the Center for Drug Evaluation and Research Advisory Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville, MD 20857. Seating is limited and available only on a first-come, first-served basis. Please note there is very limited parking in the vicinity of 5630 Fishers Lane, but it is near the Twinbrook Metro station. Please bring picture identification in order to clear building security.

Contact: Steven I. Hirschfeld, Center for Drug Evaluation and Research (HFD–150), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1532, e-mail: HIRSCHFELDS@CDER.FDA.GOV.

SUPPLEMENTARY INFORMATION: FDA is announcing a public workshop, cosponsored with the AAP, regarding pediatric oncology drug development. On January 4, 2002, the President signed into law the Best Pharmaceuticals for Children Act (Public Law 107–109). Section 15 of the Best Pharmaceuticals for Children Act (Section 15) relates to the subcommittee.

Section 15 directs the subcommittee, in carrying out ''the mission of reviewing and evaluating the data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of pediatric cancers,'' to:

- Evaluate and, to the extent practicable, prioritize new and emerging therapeutic alternatives available to treat pediatric cancer;
- Provide recommendations and guidance to help ensure that children with cancer have timely access to the most promising new cancer therapies; and
- Advise on ways to improve consistency in the availability of new therapeutic agents.

The agency is seeking public input to inform its future decisionmaking in regard to Section 15.

The agency encourages individuals, patient advocates, industry, consumer groups, health care professionals, researchers, and other interested persons to attend this public workshop.

Requests to Make Oral Presentations: The public workshop agenda allows opportunities for oral presentations from interested persons. If you desire to make a formal oral presentation, please notify the contact person (see the *Contact* section of this document) before July 17, 2002, and provide your name,